0000000000441656

AUTHOR

Anne K. Laib

showing 1 related works from this author

Serum concentrations of hydroxybupropion for dose optimization of depressed patients treated with bupropion.

2014

Background Bupropion is a dopamine and norepinephrine reuptake inhibitor approved for the treatment of depression and smoking cessation. According to the recently published reviews, it is a candidate for therapeutic drug monitoring (TDM) to improve therapeutic outcomes and reduce risks of intolerability or intoxication. In practice, however, the use of TDM is limited due to the chemical instability of bupropion. This investigation sought to determine if the major, active, and chemically stable metabolite 4-hydroxybupropion is a suitable measure to guide antidepressant drug therapy with bupropion. Methods 4-Hydroxybupropion serum levels were measured using a newly developed and validated hig…

Malemedicine.medical_specialtyUrologyNorepinephrine reuptake inhibitorPharmacokineticsmedicineHumansPharmacology (medical)BupropionChromatography High Pressure LiquidRetrospective StudiesPharmacologyBupropionDepressive Disordermedicine.diagnostic_testbusiness.industryTherapeutic effectHydroxybupropionMiddle AgedTherapeutic drug monitoringArea Under CurveClinical Global ImpressionAntidepressantAntidepressive Agents Second-GenerationFemalebusinessmedicine.drugHalf-LifeTherapeutic drug monitoring
researchProduct